NEPHROS Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>NI</div>
NEPH -- USA Stock  

USD 6.88  0.23  3.46%

The next fiscal quarter end is expected on the 30th of September 2020. The stock goes through an active upward rally. While some baby boomers are getting worried about their positions in healthcare space, it is entirely reasonable to concentrate on NEPHROS INC as a possible position for your existing portfolio. We will analyze why NEPHROS INC investors may still consider a stake in the business given the current economic outlook.
Published over three weeks ago
View all stories for NEPHROS INC | View All Stories
Do analysts believe NEPHROS INC (NASDAQ:NEPH) will continue to rise?
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NEPHROS INC has an asset utilization ratio of 344.19 percent. This implies that the company is making $3.44 for each dollar of assets. An increasing asset utilization means that NEPHROS INC is more efficient with each dollar of assets it utilizes for everyday operations.
What is the right price you would pay to acquire a share of NEPHROS INC? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with NEPHROS INC this year

Annual and quarterly reports issued by NEPHROS INC are formal financial statements that are published yearly and quarterly and sent to NEPHROS stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as NEPHROS INC often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How NEPHROS utilizes its cash?

To perform a cash flow analysis of NEPHROS INC, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash NEPHROS INC is receiving and how much cash it distributes out in a given period. The NEPHROS INC cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. NEPHROS INC Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (2.28 Million)

Acquisition by Andrew Astor of 152064 shares of NEPHROS INC subject to Rule 16b-3

Legal trades by NEPHROS INC insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
NEPHROS insider trading alert for grant of stock option (right to buy) by Andrew Astor, PresidentCEOCFO, on 26th of August 2020. This event was filed by Nephros Inc with SEC on 2020-08-26. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is NEPHROS a risky opportunity?

Let's check the volatility. NEPHROS is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind NEPHROS (NASDAQ:NEPH) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. locking in a share of a NEPHROS INC stock makes you a part-owner of that company.

NEPHROS INC Current Consensus

Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering NEPHROS INC. The NEPHROS consensus assessment is calculated by taking the average estimates from all of the analysts covering NEPHROS INC

Strong Buy
2
Buy
1
Strong Buy266.67
Buy133.33
Hold00.0
Sell00.0
Strong Sell00.0

Another 3 percent rise for NEPHROS INC

The variance is down to 10.75 as of today. As of the 27th of September, NEPHROS INC secures the risk adjusted performance of (0.15), and Mean Deviation of 2.5. In respect to fundamental indicators, the technical analysis model lets you check practical technical drivers of NEPHROS INC, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for NEPHROS INC, which can be compared to its peers in the industry. Please verify NEPHROS INC variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if NEPHROS INC is priced more or less accurately, providing market reflects its recent price of 6.43 per share. Given that NEPHROS INC has jensen alpha of (0.43), we recommend you to check NEPHROS INC's last-minute market performance to make sure the company can sustain itself at some point in the future.

The Bottom Line

While some companies in the medical instruments & supplies industry are either recovering or due for a correction, NEPHROS may not be as strong as the others in terms of longer-term growth potentials. On the whole, as of the 27th of September 2020, our overall 30 days advice on the company is Strong Sell. However, we believe NEPHROS INC is currently undervalued with very high probability of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of NEPHROS INC. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com